Chudleigh Richard A, Bain Stephen C
Singleton Hospital, Swansea Bay University Health Board.
Diabetes Research Unit, Swansea University Medical School , UK.
Expert Rev Clin Pharmacol. 2020 Jul;13(7):675-684. doi: 10.1080/17512433.2020.1776108. Epub 2020 Jul 7.
Current estimates suggest that approximately 10% of the global adult population have type 2 diabetes. In recent years there has been a significant increase in the therapeutic options available for its treatment. This article examines the use of injectable semaglutide in the treatment of type 2 diabetes.
We will describe the global problem posed by type 2 diabetes followed by consideration of the glucagon-like peptide 1 receptor agonist class of glucose lowering therapies. The focus is then shifted to semaglutide and a description of the large phase 3 pre-approval trial programme known as SUSTAIN. There is consideration of glucose control, the primary end-point of the phase 3 programme, as well as secondary end-points such as weight and blood pressure. There follows a précis of the cardiovascular outcomes trial for subcutaneous semaglutide (SUSTAIN 6) and the post-approval publications. As well as the SUSTAIN trial programme we used PubMed to identify relevant publications.
This section discusses the position of semaglutide and the risks and benefits versus other once weekly GLP-1RAs and finally the development of an oral version of semaglutide, which has recently been approved in the United States.
目前的估计表明，全球约10%的成年人口患有2型糖尿病。近年来，其治疗可用的疗法选择显著增加。本文探讨注射用司美格鲁肽在2型糖尿病治疗中的应用。
我们将描述2型糖尿病带来的全球问题，随后考虑胰高血糖素样肽-1受体激动剂类降糖疗法。然后重点转向司美格鲁肽，并描述名为SUSTAIN的大型3期批准前试验项目。会考虑血糖控制，即3期项目的主要终点，以及体重和血压等次要终点。接下来是皮下注射司美格鲁肽的心血管结局试验（SUSTAIN 6）及批准后发表文章的概述。除了SUSTAIN试验项目，我们还利用PubMed来识别相关出版物。
本节讨论司美格鲁肽的地位以及与其他每周一次的胰高血糖素样肽-1受体激动剂相比的风险和益处，最后讨论司美格鲁肽口服制剂的研发情况，该制剂最近已在美国获批。
